Successful imatinib treatment of cardiac involvement of FIP1L1-PDGFRA-positive chronic eosinophilic leukemia followed by severe hepatotoxicity

International Journal of Hematology

Volumn 86, Issue 3, 2007, Pages 233-237

  Arai, Ayako ^a   Yan, Weihua ^a   Wakabayashi, Shihoko ^a   Hayashi, Shin ^a   Inazawa, Johji ^a   Miura, Osamu ^a  

^a TOKYO MEDICAL AND DENTAL UNIVERSITY   (Japan)

Author keywords

Chronic eosinophilic leukemia; FIP1L1 PDGFRA; Hypereosinophilic syndrome; Imatinib

Indexed keywords

FIP1L1 PROTEIN; FUROSEMIDE; HYBRID PROTEIN; IMATINIB; PLATELET DERIVED GROWTH FACTOR ALPHA RECEPTOR; PREDNISOLONE; UNCLASSIFIED DRUG;

ADULT; ARTICLE; CASE REPORT; CHROMOSOME 4Q; CHROMOSOME DELETION; DISEASE SEVERITY; EOSINOPHILIC LEUKEMIA; EXON; FLUORESCENCE IN SITU HYBRIDIZATION; GENE SEQUENCE; GENETIC TRANSCRIPTION; HEART FAILURE; HEART LEFT VENTRICLE; HEART VENTRICLE THROMBOSIS; HUMAN; INTRON; LIVER BIOPSY; LIVER DYSFUNCTION; LIVER TOXICITY; LYMPHOCYTIC INFILTRATION; MALE; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SEQUENCE ANALYSIS; TREATMENT OUTCOME; TREATMENT RESPONSE;

ADULT; ANTINEOPLASTIC AGENTS; BIOPSY; CHROMOSOMES, HUMAN, PAIR 4; CHRONIC DISEASE; EXONS; FEMALE; FUROSEMIDE; GLUCOCORTICOIDS; HEART DISEASES; HEART VENTRICLES; HEPATOCYTES; HUMANS; HYPEREOSINOPHILIC SYNDROME; INTRONS; LIVER DISEASES; LYMPHOCYTES; MALE; MIDDLE AGED; MRNA CLEAVAGE AND POLYADENYLATION FACTORS; NECROSIS; ONCOGENE PROTEINS, FUSION; PIPERAZINES; PREDNISOLONE; PYRIMIDINES; RECEPTOR, PLATELET-DERIVED GROWTH FACTOR ALPHA; SEQUENCE DELETION; SODIUM POTASSIUM CHLORIDE SYMPORTER INHIBITORS; THROMBOSIS;

EID: 36048948407     PISSN: 09255710     EISSN: None     Source Type: Journal    
DOI: 10.1532/IJH97.07032     Document Type: Article

References (19)

1. Cools J, DeAngelo DJ, Gotlib J, et al. A tyrosine kinase created by fusion of the PDGFRA and FIP1L1 genes as a therapeutic target of imatinib in idiopathic hypereosinophilic syndrome. N Engl J Med. 2003;348:1201-1214.
2. Klion AD, Robyn J, Akin C, et al. Molecular remission and reversal of myelofibrosis in response to imatinib mesylate treatment in patients with the myeloproliferative variant of hypereosinophilic syndrome. Blood. 2004;103:473-478.
3. Ayoub WS, Geller SA, Tran T, Martin P, Vierling JM, Poordad FF. Imatinib (Gleevec)-induced hcpatotoxicity. J Clin Gastroenterol. 2005;39:75-77.
4. Cross TJ, Bagot C, Portmann B, Wendon J, Gillett D. Imatinib mesylate as a cause of acute liver failure. Am J Hematol. 2006;81:189-192.
5. Ferrero D, Pogliani EM, Rege-Cambrin G, et al. Corticosteroids can reverse severe imatinib-induced hepatotoxieity. Haematologica. 2006;91(suppl 6):ECR27.
6. Ikuta K, Torimoto Y, Jimbo J, et al. Severe hepatic injury caused by imatinib mesylate administered for the treatment of chronic myeloid leukemia and the efficacy of prednisolone for its management. Int J Hematol. 2005;82:343-346.
7. James C, Trouette H, Marit G, Cony-Makhoul P, Mahon FX. Histological features of acute hepatitis after imatinib mesylate treatment. Leukemia. 2003;17:978-979.
8. Ohyashiki K, Kuriyama Y, Nakajima A, et al. Imatinib mesylate-induced hepato-toxicity in chronic myeloid leukemia demonstrated focal necrosis resembling acute viral hepatitis. Leukemia. 2002;16:2160-2161.
9. Robyn J, Lemery S, Philip McCoy J, et al. Multilineage involvement of the fusion gene in patients with FIP1L1/PDGFRA-positive hypereosinophilic syndrome. Br J Haematol. 2006;132:286-292.
10. Griffin JH, Leung J, Bruner RJ, Caligiuri MA, Briesewitz R. Discovery of a fusion kinase in EOL-1 cells and idiopathic hypereosinophilic syndrome. Proc Natl Acad Sci U S A. 2003;100:7830-7835.
11. Klion AD, Noel P, Akin C, et al. Elevated serum tryptase levels identify a subset of patients with a myeloproliferative variant of idiopathic hypereosinophilic syndrome associated with tissue fibrosis, poor prognosis, and imatinib responsiveness. Blood. 2003;101:4660-4666.
12. Rose C, Dupire S, Roche-Leslienne C, et al. Sustained molecular response with imatinib in a leukemic form of idiopathic hypereosinophilic syndrome in relapse after allograft. Leukemia. 2004;18:354-355.
13. Vandenberghe P, Wlodarska I, Michaux L, et al. Clinical and molecular features of FIP1L1-PDGFRA (+) chronic eosinophilic leukemias. Leukemia. 2004;18:734-742.
14. Weller PF, Bubley GJ. The idiopathic hypereosinophilic syndrome. Blood. 1994;83:2759-2779.
15. Florian S, Esterbauer H, Binder T, et al. Systemic mastocytosis (SM) associated with chronic eosinophilic leukemia (SM-CEL): detection of FIP1L1/PDGFRα, classification by WHO criteria, and response to therapy with imatinib. Leak Res. 2006;30:1201-1205.
16. La Starza R, Specchia G, Cuneo A, et al. The hypereosinophilic syndrome: fluorescence in situ hybridization detects the del(4)(q12)-FIP1L1/PDGFRA but not genomic rearrangements of other tyrosine kinases. Haematologica. 2005;90:596-601.
17. Musial J, Brzezinska-Kolarz B, Sanak M, Szczeklik A. Improved cardiac function in a patient with hypereosinophilic syndrome treated with imatinib. Eur J Haematol. 2005;75:87-88.
18. Rotoli B, Catalano L, Galderisi M, et al. Rapid reversion of Loeffler's endocarditis by imatinib in early stage clonal hypereosinophilic syndrome. Leak Lymphoma. 2004;45:2503-2507.
19. Lin NU, Sarantopoulos S, Stone JR, et al. Fatal hepatic necrosis following imatinib mesylate therapy. Blood. 2003;102:3455-3456.